139516-64-6

Basic information

• Product Name: 1-(2-FLUOROBENZOYL)PIPERAZINE
• Synonyms: 1-(2-fluorobenzoyl)piperazine hydrochloride;MFCD14583048;ethyl 3-amino-3-(3-cyanophenyl)propanoate
• CAS NO: 139516-64-6
• Molecular Formula: C₁₁H₁₃FN₂O
• Molecular Weight: 208.24
• Mol File: 139516-64-6.mol

Chemical Properties

• Boiling Point: 357.1°C at 760 mmHg
• Flash Point: 169.8°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 2.78E-05mmHg at 25°C
• Refractive Index: 1.544
• CAS DataBase Reference: 1-(2-FLUOROBENZOYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-FLUOROBENZOYL)PIPERAZINE(139516-64-6)
• EPA Substance Registry System: 1-(2-FLUOROBENZOYL)PIPERAZINE(139516-64-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 139516-64-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Synthesis:
1-(2-Fluorobenzoyl)piperazine is used as a building block for the synthesis of various drugs and bioactive molecules, contributing to the development of new therapeutic agents.
Used in Medicinal Chemistry:
1-(2-Fluorobenzoyl)piperazine is employed as a key component in the design and synthesis of novel compounds with potential antipsychotic and antihistaminic properties, targeting the treatment of mental health disorders and allergic reactions.
Used in Neurological Disorder Research:
1-(2-Fluorobenzoyl)piperazine is used as a potential ligand for imaging studies in PET and SPECT, aiding in the investigation and understanding of neurological disorders and their underlying mechanisms.
Used in Serotonin Receptor Interaction Studies:
1-(2-Fluorobenzoyl)piperazine is utilized in research to study its interaction with serotonin receptors, which may provide insights into the development of new treatments for mood and anxiety disorders.

InChI:InChI=1/C12H14N2O2/c1-2-16-12(15)7-11(14)10-5-3-4-9(6-10)8-13/h3-6,11H,2,7,14H2,1H3

Upstream product

• 110-85-0 piperazine 
• 393-52-2 2-Fluorobenzoyl chloride 
• 828298-39-1 tert-butyl 4-(2-fluorobenzoyl)piperazine-1-carboxylate 
• 142-64-3 piperazine dihydrochloride 
• 107599-83-7 (2-fluorobenzoyl)imidazoline 
• 445-29-4 o-fluoro-benzoic acid 
• 121-44-8 triethylamine 

Downstream Products

• 89292-78-4 1-(o-fluorobenzyl)piperazine 

Relevant articles and documents

Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms

We report the synthesis and biochemical evaluation of a series of substituted 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamides (5a-s) developed as inhibitors of druggable carbonic anhydrase (CA) isoforms, as tools for the identification of new therapeu

Design, synthesis, and biological evaluation of matrine derivatives possessing piperazine moiety as antitumor agents

Using matrine (1) as the lead compound, a series of new piperazinyl matrine derivatives were designed, synthesized and evaluated for their antitumor activities in vitro and in vivo. Structure activity relationship (SAR) analysis indicated that introductio

A N, 6 diphenyl pyrimidine -4 - amine Bcr - Abl inhibitor and its preparation method and application (by machine translation)

The invention discloses a N, 6 diphenyl pyrimidine - 4 - amine Bcr - Abl inhibitor and its preparation method and application, the structural formula of the inhibitor for the wherein R is a single substituent or double-substituent, substituent is alkyl or halogen; R1 As a single substituent or double-substituent, substituent is alkyl or halogen. The series of inhibitors in vitro ABL1 kinase restraining effects, and can inhibit the proliferation of tumor cells, can be used for anti-tumor pharmaceutical preparation, in particular CML (chronic granulocytic leukemia) drug. The invention provides N, 6 diphenyl pyrimidine - 4 - amine Bcr - Abl inhibitor preparation method, raw materials are apt, mild reaction conditions, the reaction process is simple in operation, reagent used and cheap. (by machine translation)

Synthesis, characterization, and anti-inflammatory activities of methyl salicylate derivatives bearing piperazine moiety

In this study, a new series of 16 methyl salicylate derivatives bearing a piperazine moiety were synthesized and characterized. The in vivo anti-inflammatory activities of target compounds were investigated against xylol-induced ear edema and carrageenan-induced paw edema in mice. The results showed that all synthesized compounds exhibited potent anti-inflammatory activities. Especially, the anti-inflammatory activities of compounds M15 and M16 were higher than that of aspirin and even equal to that of indomethacin at the same dose. In addition, the in vitro cytotoxicity activities and anti-inflammatory activities of four target compounds were performed in RAW264.7 macrophages, and compound M16 was found to significantly inhibit the release of lipopolysaccharide (LPS)-induced interleukin (IL)-6 and tumor necrosis factor (TNF)-α in a dose-dependent manner. In addition, compound M16 was found to attenuate LPS induced cyclooxygenase (COX)-2 up-regulation. The current preliminary study may provide information for the development of new and safe anti-inflammatory agents.

Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib

In order to expand the structural diversity of Bcr-Abl inhibitors, twenty hybrids (series E and P) have been synthesized and characterized based on Imatinib and GNF-2. Their biological activities were evaluated in vitro against human leukemia cells. Most compounds exhibited potent antiproliferative activity against K562 cells, especially for compounds E4, E5 and E7. Furthermore, these new hybrids were also screened for Abl kinase inhibitory activity, and some of them inhibited Abl kinase with low micromolar IC50 values. In particular, compound P3 displayed the most potent activity with IC50 value of 0.017 μM comparable with that of Imatinib. Molecular docking studies indicated that these novel hybrids fitted well with the active site of Bcr-Abl. These results suggested the great potential of these compounds as novel Bcr-Abl inhibitors.

Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site

Bcr-Abl plays an essential role in the pathogenesis and development of chronic myeloid leukaemia (CML). Inhibition of Bcr-Abl has great potential for therapeutic intervention in CML. In order to obtain novel and potent Bcr-Abl inhibitors, twenty seven 4,6-disubstituted pyrimidines were synthesized and evaluated herein. The biological results indicated that four compounds of them (C4, C5, C16, and C23) were potent Bcr-Abl inhibitors which were comparable to positive control. Moreover, C4 and C5 displayed promising antiproliferative activity against K562 cells. The results suggested that these 4,6-disubstituted pyrimidines could serve as promising leads for further optimization of Bcr-Abl inhibitors.

CDI-mediated monoacylation of symmetrical diamines and selective acylation of primary amines of unsymmetrical diamines

A highly efficient and green protocol for monoacylation of symmetrical diamines and chemoselective acylation of primary amines of unsymmetrical diamines has been developed.

Certain substituted 1-aryl-3-piperazin-1′-yl propanones

Disclosed are compounds of formula I: wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1and Ar2independently represent aryl groups; and Y is hydrogen; o

Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease

Disclosed are compounds of formula I: STR1 or the pharmaceutically acceptable salts thereof wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1 and Ar2 i

Substituted 1-aryl-3-piperazin-1'-yl propanones

Disclosed are compounds of formula I: STR1 wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar1 and Ar2 independently represent aryl groups; and Y is hydr